Back to search results

rTMS for Dystonia Brain Connectivity

This study is exploring how a treatment called repetitive transcranial magnetic stimulation (rTMS) affects brain activity in people with dystonia. Specifically, it uses a modified form of rTMS called continuous theta-burst stimulation (cTBS), which mimics natural brain rhythms to help calm overactive brain areas. We want to see how this treatment changes the connections in the brain, measured by resting-state fMRI scans. You might be able to join if you are between 18 and 80 years old, have dystonia (involuntary muscle movements), and have a normal neurological exam otherwise. The study aims to see if rTMS can change brain connectivity within two to four weeks after treatment. The current status of this study is unclear, and it plans to enroll 10 participants.

Study design
This is an interventional study with an unclear status, planning to enroll 10 participants. It uses a specific type of repetitive transcranial magnetic stimulation (rTMS) called continuous theta-burst stimulation (cTBS).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, evaluating rs-fMRI changes, is measured two to four weeks after rTMS treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07626216

Impact of rTMS on Abnormal Cortical fMRI in Patients With Dystonia

Recruiting
EARLY_PHASE1Ages 18–80InterventionalTreatment
Northwell Health
~10 participants
Updated 2026-06-04 on ClinicalTrials.gov
What's tested:Transcranial Magnetic Stimulation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluating rs-fMRI Changes Following rTMS Treatment
Measured over Two to four weeks.

Conditions

Dystonia Disorder

Explore related trials

DystoniaTHAP1 wt AlleleTOR1A wt Allele

NCT07626216

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Northwell Health/Feinstein Institutes

    Manhasset, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Celina B Fernandez, MS
[email protected]
516-562-3646
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female
18 and 80 years of age.
Patients who manifest dystonia - sustained involuntary movement of the head, neck, trunk or limbs.
The dystonia may be spontaneous or genetic, specifically DYT1 or DYT6 and then only those patients who are demonstrating dystonia. The patient/subject will have a normal neurological exam except for dystonia.

Exclusion

Heredodegenrative dystonia of the type DYT8,9 or 10.
Past history of head trauma, stroke, epilepsy, demyelinating disease
Hypertension in excess of 160mmHg systolic and 90mmHg diastolic
Congestive heart failure
Diabetes
Past psychiatric conditions: e.g., depression
Systemic metabolic disease: e.g., Wilson's disease, progressive neurodegenerative disease (like supranuclear palsy or corticobasal ganglionic degeneration)
Magnetizable incorporated metal parts - like pacemakers
History or diagnosis of Parkinson's disease
Presence of myoclonus
No previous surgery for dystonia
Long term exposure to benzodiazepines, neuroleptics or anticonvulsants
No botulinum toxin within 12 weeks of baseline assessment and fMRI.
Moderate to severe cognitive impairment (judged by a minimental status of \<24.)

What this trial measures

  • Evaluating rs-fMRI Changes Following rTMS TreatmentTwo to four weeks.

    The primary objective is to identify and modify replicable brain networks in dystonia patients using rs-fMRI. These networks reflect underlying disease processes, clinical symptomatology or both. The primary endpoint is change in the rs-fMRI derived network after rTMS treatment for two or four weeks, or both. We expect there to be changes at two and four weeks. We will then analyze the robustness of these changes in the repeat fMRI one week after treatment ends. Initially, identification and validation of the dystonia pattern from the resting state MRI will occur; it is a task with which we are familiar and is detailed in our recent manuscript.